Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [Studio randomizzato di fase III sull'ottimizzazione della combinazione di bevacizumab con FOLFOX/OXXEL nel trattamento dei pazienti affetti da carcinoma del colon-retto metastatico]

Trial Profile

Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [Studio randomizzato di fase III sull'ottimizzazione della combinazione di bevacizumab con FOLFOX/OXXEL nel trattamento dei pazienti affetti da carcinoma del colon-retto metastatico]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms OBELICS
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Results (n=230) assessing the efficacy and tolerability of bevacizumab administered prior to or at the same time as the mFOLFOX/OXXEL chemotherapy regimen, containing oxaliplatin, folinic acid, fluorouracil, and capecitabine, in patients with colorectal adenomas, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Sep 2017 Primary endpoint (Objective Response rate) has not been met, as per results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top